- Home
- APLT vs KULR Comparison
APLT vs KULR Comparison
Compare APLT & KULR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- KULR
- Stock Information
- Founded
- APLT 2016
- KULR 2013
- Country
- APLT United States
- KULR United States
- Employees
- APLT N/A
- KULR N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- KULR Electrical Products
- Sector
- APLT Health Care
- KULR Technology
- Exchange
- APLT Nasdaq
- KULR Nasdaq
- Market Cap
- APLT 178.6M
- KULR 166.5M
- IPO Year
- APLT 2019
- KULR N/A
- Fundamental
- Price
- APLT $1.28
- KULR $3.79
- Analyst Decision
- APLT Buy
- KULR Strong Buy
- Analyst Count
- APLT 5
- KULR 2
- Target Price
- APLT $4.13
- KULR $40.00
- AVG Volume (30 Days)
- APLT 5.5M
- KULR 3.1M
- Earning Date
- APLT 11-10-2025
- KULR 11-12-2025
- Dividend Yield
- APLT N/A
- KULR N/A
- EPS Growth
- APLT N/A
- KULR N/A
- EPS
- APLT N/A
- KULR N/A
- Revenue
- APLT $121,000.00
- KULR $12,977,975.00
- Revenue This Year
- APLT N/A
- KULR $89.99
- Revenue Next Year
- APLT $5,935.35
- KULR $97.50
- P/E Ratio
- APLT N/A
- KULR N/A
- Revenue Growth
- APLT N/A
- KULR 35.81
- 52 Week Low
- APLT $0.30
- KULR $2.16
- 52 Week High
- APLT $10.62
- KULR $43.92
- Technical
- Relative Strength Index (RSI)
- APLT 60.36
- KULR 37.21
- Support Level
- APLT $1.16
- KULR $3.88
- Resistance Level
- APLT $1.50
- KULR $4.35
- Average True Range (ATR)
- APLT 0.14
- KULR 0.37
- MACD
- APLT -0.02
- KULR -0.10
- Stochastic Oscillator
- APLT 61.64
- KULR 2.45
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.